Mesenchymal stem cells (MSCs) have been used experimentally for treating inflammatory disorders, partly owing to their immunosuppressive properties. The goal of the study was to determine whether TLR ligands can enhance the therapeutic efficacy of bone marrow-derived MSCs for the treatment of inflammatory bowel disease. Mice (C57BL6) were administered with 4% dextran sulfate sodium (DSS) in drinking water for 7 days and injected with MSCs on days 1 and 3 following DSS ingestion. Our results demonstrated that among various TLR ligands, MSCs treated with polyinosinic-polycytidylic acid [poly(I:C)], which is a TLR3 ligand, more profoundly induced IDO, which is a therapeutically relevant immunosuppressive factor, without any observable phenotype change in vitro. The poly(I:C)-treated MSCs attenuated the pathologic severity of DSS-induced murine colitis when injected i.p. but not i.v. In summary, preconditioning MSCs with poly(I:C) might improve their efficacy in treating DSS-induced colitis, and this effect at least partly depends on the enhancement of their immunosuppressive activity through increasing their production of IDO.

中文翻译：

---

用 Poly(I:C) 预处理诱导吲哚胺 2,3-双加氧酶可提高 MSC 在 DSS 诱导的结肠炎中的治疗效果

间充质干细胞 (MSC) 已在实验上用于治疗炎症性疾病，部分原因是它们具有免疫抑制特性。该研究的目的是确定 TLR 配体是否可以增强骨髓来源的 MSCs 治疗炎症性肠病的疗效。小鼠 (C57BL6) 在饮用水中服用 4% 葡聚糖硫酸钠 (DSS) 7 天，并在摄入 DSS 后的第 1 天和第 3 天注射 MSC。我们的结果表明，在各种 TLR 配体中，用聚肌苷酸 [poly(I:C)]（一种 TLR3 配体）处理的 MSCs 更显着地诱导 IDO，这是一种治疗相关的免疫抑制因子，没有任何可观察到的表型变化。体外。聚（I：